Anti-CD84 Antibody CDR Engineering for Tumor Microenvironment Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for anti-CD84 antibodies that can effectively act on the tumor microenvironment to induce a favorable immune response and promote tumor eradication.
Innovation Solution
Development of anti-CD84 antibodies with specific CDR sequences (SEQ ID NOs: 19, 20, 21, 22, 23, 24, 39, 40, 41, 42, 43, 57, 58, 59, 60, 61, 75, 76, 77, 78, 79, 93, 94, 95, 96, 97, 98) that bind to the CD84 epitope, and their use in pharmaceutical compositions for cancer treatment, along with methods for antibody production and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used, then general immune response is activated, but specific action on tumor microenvironment is insufficient
Solution Approach 1:
The patent applies local quality by designing antibodies with specific CDR sequences (CDR-H1: SEQ ID NO:75, CDR-H2: SEQ ID NO:76, CDR-H3: SEQ ID NO:77, CDR-L1: SEQ ID NO:78, CDR-L2: SEQ ID NO:79, CDR-L3: SEQ ID NO:80) that are optimized to recognize and bind to CD84 molecules specifically expressed in the tumor microenvironment. This localized optimization of antibody structure enables selective targeting of tumor-associated CD84 while maintaining general antibody functions, thereby resolving the contradiction between reliable tumor eradication and adaptability to tumor microenvironment.
2Measurement precision
If antibody structure is highly specific to bind CD84 epitope, then binding affinity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs segmentation by defining the antibody structure in discrete, modular components with specific CDR sequences. The antibody is characterized by six distinct CDR regions (CDR-H1 through CDR-H3 and CDR-L1 through CDR-L3) with predetermined sequences that can be independently designed and assembled. This segmented approach allows for precise epitope binding through specific sequence combinations while simplifying manufacturing through modular assembly of standardized antibody frameworks with defined CDR insertions.
Data Source
AI summary
Provided herein are, inter alia, antibodies (e.g. humanized antibodies, chimeric antibodies, monoclonal antibodies, antibody fragments (e.g. scFvs)), which bind Cluster of Differentiation 84 (CD84) with high efficiency and specificity. The antibodies provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for treating cancer and other CD84-related diseases.